Rathbones Group’s Definium Therapeutics DFTX Stock Holding History

Rathbones Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Sell	22,800 -7,400	-25%	-$183K	﹤0.01%	359
2026 Q1	$571K	Hold	30,200	–	–	﹤0.01%	437
2025 Q4	$404K	Hold	30,200	–	–	﹤0.01%	482
2025 Q3	$356K	Buy	30,200 +2,000	+7%	+$18.7K	﹤0.01%	493
2025 Q2	$183K	Hold	28,200	–	–	﹤0.01%	564
2025 Q1	$165K	Buy	28,200 +8,000	+40%	+$57.3K	﹤0.01%	543
2024 Q4	$141K	Hold	20,200	–	–	﹤0.01%	554
2024 Q3	$115K	Sell	20,200 -4,000	-17%	-$27.8K	﹤0.01%	559
2024 Q2	$174K	Hold	24,200	–	–	﹤0.01%	556
2024 Q1	$227K	Sell	24,200 -800	-3%	-$4.56K	﹤0.01%	533
2023 Q4	$91.5K	Hold	25,000	–	–	﹤0.01%	567
2023 Q3	$78.3K	Buy	+25,000	New	+$103K	﹤0.01%	580

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Rathbones Group's DFTX Position: Q2 2026 in Review

Rathbones Group reduced its Definium Therapeutics (DFTX) stake by 25% in Q2 2026, selling an estimated $183K and leaving 22,800 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Rathbones Group first reported a position in DFTX in Q3 2023 and has held it in 12 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Rathbones Group held 22,800 shares of Definium Therapeutics worth $1.07M as of Q2 2026.
Rathbones Group sold 7,400 Definium Therapeutics shares in Q2 2026, an estimated $183K.
Definium Therapeutics made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #359 holding.
Rathbones Group first reported a position in Definium Therapeutics in Q3 2023 and has held it in 12 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.